Medicortex Finland Oy Announces Issuance of a Patent for Brain Injury Biomarker
16.4.2020 09:55:00 EEST | Business Wire | Press release
Medicortex Finland Oy, an innovative biopharmaceutical company focused on the development of diagnostics and drug treatment for mild traumatic brain injury (TBI), today announced that the European Patent Office (EPO) has issued a patent covering company’s new diagnostic kit technology.
“We are extremely pleased with the growth of the patent portfolio related to the TBI testing. This new issuance continues to expand the intellectual property portfolio covering methods to be used for detection of concussion biomarkers. The issuance of this patent is another step in the development of a robust patent portfolio relating to a new strategy to help identify mild TBI” said Dr. Harel Adrian, Chief Executive Officer of Medicortex.
Medicortex is currently developing a rapid diagnostic kit for detection of concussion and mild traumatic brain injury from urine or saliva. The kit is based on specific biomarkers that the company has discovered from body fluids following brain injury. Such a rapid test will fulfill the urgent need to improve the detection of brain injury especially in mild cases – which are potentially harmful but admittedly difficult to diagnose with the contemporary means. The issued patent covers the core technology and method of utilizing glycan-based biomarkers for detection of mild traumatic brain injury, which is presently the company’s main development program.
Medicortex’s patent portfolio comprises of biomarkers for brain injury diagnostics and drug candidates for halting the progression of brain injury. All innovations have been developed by the company. The comprehensive patent coverage secures exclusivity to develop the products, and the company’s strategy is to actively seek new patentable innovations from its biomarker and drug development programs.
About Medicortex
Medicortex Finland Oy is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect the presence of a head injury. The company has the technology to capture biomarkers from urine and saliva and to develop them into an affordable diagnostic tool. Medicortex was established by an Israeli neurobiologist Adrian Harel (Ph.D., MBA) in 2014, and the company is based in Turku, Finland.
Key words: brain injury, head injury, concussion, diagnostics, TBI, early detection, trauma, clinical trial, new patent
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Medicortex assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200415005854/en/
Contact information
Medicortex Finland Oy
Dr. Adrian Harel - CEO
Tel. +358 (0) 400 488 817
adrian.harel@medicortex.fi
http://www.medicortex.fi
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riskified Partners with Outpayce from Amadeus to Enable and Secure Payments for Airlines and Travel Merchants Worldwide7.4.2026 15:00:00 EEST | Press release
Riskified, a leader in ecommerce fraud and risk intelligence, today announced a partnership with Outpayce from Amadeus. This partnership boosts Outpayce’s trusted travel payment platform with Riskified’s AI-powered fraud prevention suite and Chargeback Guarantee model, creating a game-changing solution for airlines worldwide. The landscape of airline payments is evolving, and we're proud to share a major milestone that will reshape the way airlines approach fraud management. Outpayce from Amadeus is a global travel payments orchestrator and specialized fintech enabler, empowering airlines and travel merchants to streamline complex payment processes, optimize costs, and enhance customer experiences. Purpose-built for the travel industry, Outpayce delivers innovation, flexibility, and seamless integration within the Amadeus ecosystem, supporting secure, efficient, and scalable payment operations across the entire traveler journey. With Riskified integrating into Outpayce’s ecosystem, car
IQM and Real Asset Acquisition Corp. Announce Confidential Submission of Draft Registration Statement on Form F-4 in Connection With Proposed Business Combination7.4.2026 14:12:00 EEST | Press release
IQM Finland Oy, a global leader in deployed on-premises, full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp., a special purpose acquisition company (Nasdaq: RAAQ) (“RAAQ”), today announced the confidential submission of the draft registration statement on Form F-4 (the “Registration Statement”) filed by IQM with the U.S. Securities and Exchange Commission (“SEC”) relating to their proposed business combination. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407372076/en/ IQM Quantum Computers The submission of the Registration Statement marks an important milestone toward the completion of the proposed business combination, which will result in IQM becoming a publicly traded company. The business combination remains subject to approval by RAAQ shareholders, the Registration Statement being declared effective by the SEC, and other customary closin
Reckitt Accelerates Innovation with NIQ AI Insights, reporting up to 65% faster research7.4.2026 13:30:00 EEST | Press release
NIQ (NYSE: NIQ), a global leader in consumer intelligence, today shared new results from Reckitt’s use of NIQ BASES AI Screener, demonstrating how AI-powered insights and synthetic data are transforming innovation speed and effectiveness. The case study highlights how Reckitt has accelerated concept development while improving performance outcomes—bringing more relevant products to market, faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407069246/en/ NIQ BASES AI Screener As companies face growing pressure to innovate quickly in an increasingly complex consumer landscape, traditional research and development cycles can slow decision-making. Reckitt’s adoption of AI-powered screening reflects a broader shift toward predictive, data-driven innovation—where teams can test, refine, and optimize ideas before investing in physical development. Key Results from Reckitt’s Use of NIQ BASES AI Screener: 70% faster insight ge
Lincotek Appoints New Global General Manager for Its Medical Division7.4.2026 11:08:00 EEST | Press release
Lincotek today announced the appointment of Gianluca Fioravanti as Global General Manager of its Medical Division - a global solution provider for the orthopedic market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407710572/en/ Gianluca Fioravanti, Global GM Lincotek’s Medical Division Reporting directly to Group CEO Andrea Colombo, Fioravanti assumed the role as of April 7 and will help drive the business forward. He will lead the development and execution of the company’s global growth strategy, while ensuring its seamless operational implementation across all regions. This strategic appointment reflects Lincotek’s commitment to enhance the value it delivers to customers, strengthening its ability to serve them better. Fioravanti brings more than 25 years of international experience to the Group, having held senior leadership roles across operations, engineering and general management in the medical sector. With a de
Toshiba’s Breakthrough Algorithm Harnesses Edge of Chaos to Dramatically Boost Performance of its Quantum‑Inspired Computer7.4.2026 10:00:00 EEST | Press release
Toshiba Corporation has developed a breakthrough algorithm that dramatically boosts the performance of the Simulated Bifurcation Machine (SBM), its proprietary quantum‑inspired combinatorial optimization computer. The new algorithm significantly improves the probability of obtaining an optimal solution or a known best solution within a limited number of trials—referred to as the success probability, a key benchmark for evaluating combinatorial optimization technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407918434/en/ Figure 1: Results demonstrating that the newly developed third‑generation SB algorithm can find the known best solution with nearly 100% probability at the edge of chaos for a fully connected 2,000‑spin Ising problem. The SBM is designed to solve large‑scale combinatorial optimization problems in a wide range of fields, including new drug discovery, delivery route optimization, and investment por
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom